<DOC>
	<DOCNO>NCT01072942</DOCNO>
	<brief_summary>The study conduct single-center , randomize , single-blinded , placebo-controlled , dose escalation design two dose groups.Multiple-dose inhalation Ciprofloxacin inhale 50 75 mg placebo administer 16 Japanese patient COPD totalPatients moderate severe COPD , stage II III accord GOLD criterion , participate study.The study consist 2 step indicate ; start Step 1 ( 50 mg ) escalate dos Step 2 ( 75 mg ) , tolerability dose previous step confirm . In step , study conduct multiple dose study b.i.d . regimen 10 day ( day 2 11 ) randomize , single-blind , placebo-controlled design . In addition , multiple dose administration , single administration conduct subject ( day 0 12 ) .</brief_summary>
	<brief_title>To Evaluate Safety , Tolerability , Pulmonary Deposition , Pharmacokinetics Pharmacodynamics Ciprofloxacin Inhale Japanese Patients With Moderate Severe Chronic Obstructive Pulmonary Disease ( COPD , GOLD II-III )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<criteria>Adult patient COPD , 40 80 year age All patient must diagnosis COPD must meet follow spirometric criterion : Patients must relatively stable airway obstruction postbronchodilator 30 % &lt; /= Forced Expiratory Volume ( FEV1 ) &lt; /= 65 % predict normal . And postbronchodilator FEV1 / Forced Vital Capacity ( FVC ) &lt; 70 % . Patients significant respiratory disease COPD . A significant disease define disease , opinion investigator Patients medical disorder , condition history would impair patient ability participate complete study opinion investigator , patient mental disorder inappropriate communal living participation clinical study , ability give inform consent , physical disability Patients history CF Patients clinically evident bronchiectasis Patients history asthma Patients undergone thoracotomy pulmonary resection Patients relevant conspicuous finding medical history prestudy examination relate underlying disease</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Chronic Obstructive</keyword>
	<keyword>Phase I</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Microbiology</keyword>
</DOC>